Drug-induced movement disorders encompass a range of involuntary motor disturbances precipitated by exposure to certain medications, most commonly dopamine-blocking agents such as antipsychotics and ...

Everyone kept taking their usual Parkinson’s medications. After a year, the symptoms of participants in the GLP-1 group seemed to not progress as rapidly as in the placebo group. This suggested a ...

Researchers are increasingly using AI to accelerate the search for treatments for neurological conditions such as Alzheimer’s ...

The U.S. Food and Drug Administration is reviewing a new Parkinson's disease drug called tavapadon that could give people with the disease more control over their movements. If approved, it would be ...

Research from Carnegie Mellon University’s Aryn Gittis and colleagues suggests the most recognizable symptoms of Parkinson's disease — tremor and slowed movement — result from disruptions in different ...

Remepy, a pioneer in Hybrid Drugs™, today announced that the Phase IIa clinical trial of Hybridopa™, a new Hybrid Drug for Parkinson's disease, met its primary endpoint, delivering statistically ...

New research identifies two main Parkinson's disease subtypes and five subgroups, explaining why single treatments often fail ...

Breakthroughs on Parkinson's could lead to treatments for other brain ills like Lewy body dementia and Alzheimer's.

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

From special pens to earwax evaluations, a plethora of emerging diagnostics could one day be a major boon for people with the debilitating disease.